Refractory High-Grade B-Cell Lymphoma

14 clinical trials · Condition

Record	Firm	Date
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (NCT05418088)	Sumithira Vasu	2022-06-30
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma (NCT05025800)	M.D. Anderson Cancer Center	2021-10-13
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma (NCT04432506)	M.D. Anderson Cancer Center	2020-07-27
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy (NCT04409314)	University of California, San Francisco	2020-04-16
Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy (NCT04870853)	M.D. Anderson Cancer Center	2020-04-02
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma (NCT04205838)	Jonsson Comprehensive Cancer Center	2020-03-04
Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (NCT03309878)	National Cancer Institute (NCI)	2018-10-24

Every clearance here is in the API, with alerts when new ones post.